Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma.
Adult
Aged
Animals
Antigens, CD
/ metabolism
Chondrosarcoma
/ pathology
Collagen
/ pharmacology
Female
Fibroblasts
/ drug effects
Human Umbilical Vein Endothelial Cells
/ metabolism
Humans
Immunophenotyping
Male
Mice, Nude
Microvessels
/ pathology
Middle Aged
Monocytes
/ drug effects
Phenotype
Spheroids, Cellular
/ drug effects
THP-1 Cells
Time Factors
Tumor-Associated Macrophages
/ drug effects
cell migration inhibitors
chondrosarcoma
monocytes
tumor-associated macrophages
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
24 04 2020
24 04 2020
Historique:
received:
01
04
2020
revised:
21
04
2020
accepted:
23
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
23
2
2021
Statut:
epublish
Résumé
Chondrosarcomas (CHS) are malignant cartilaginous neoplasms with diverse morphological features, characterized by resistance to chemo- and radiation therapies. In this study, we investigated the role of tumor-associated macrophages (TAM)s in tumor tissues from CHS patients by immunohistochemistry. Three-dimensional organotypic co-cultures were set up in order to evaluate the contribution of primary human CHS cells in driving an M2-like phenotype in monocyte-derived primary macrophages, and the capability of macrophages to promote growth and/or invasiveness of CHS cells. Finally, with an in vivo model of primary CHS cells engrafted in nude mice, we tested the ability of a potent peptide inhibitor of cell migration (Ac-d-Tyr-d-Arg-Aib-d-Arg-NH
Identifiants
pubmed: 32344648
pii: cells9041062
doi: 10.3390/cells9041062
pmc: PMC7226304
pii:
doi:
Substances chimiques
Antigens, CD
0
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Oncoimmunology. 2013 Sep 1;2(9):e25563
pubmed: 24319632
Sarcoma. 2019 Dec 13;2019:9069272
pubmed: 31915413
J Clin Invest. 2016 Oct 3;126(10):3672-3679
pubmed: 27482883
Am J Pathol. 2006 Jan;168(1):321-30
pubmed: 16400033
J Biol Chem. 2005 Jul 1;280(26):25225-32
pubmed: 15866865
Nat Rev Immunol. 2015 Feb;15(2):73-86
pubmed: 25614318
Int J Pept Protein Res. 1990 Mar;35(3):161-214
pubmed: 2191922
J Leukoc Biol. 2006 Oct;80(4):705-13
pubmed: 16864600
Genes Chromosomes Cancer. 2012 Oct;51(10):899-909
pubmed: 22674453
Future Oncol. 2017 Mar;13(7):637-648
pubmed: 28133974
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Oncologist. 2008 Mar;13(3):320-9
pubmed: 18378543
J Cell Mol Med. 2020 Jan;24(1):13-24
pubmed: 31642585
Cancer Metastasis Rev. 2011 Mar;30(1):83-95
pubmed: 21249423
PLoS One. 2012;7(11):e50195
pubmed: 23185575
Stem Cells. 1997;15(6):398-408
pubmed: 9402652
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Nat Rev Cancer. 2011 May 26;11(7):493-501
pubmed: 21614026
Mol Cancer Ther. 2014 May;13(5):1092-104
pubmed: 24705350
Oncologist. 2019 Jan;24(1):110-116
pubmed: 30082492
Cells. 2019 Dec 23;9(1):
pubmed: 31878087
Clin Orthop Relat Res. 2002 Apr;(397):76-82
pubmed: 11953598
J Bone Oncol. 2019 Nov 26;20:100271
pubmed: 31956474
J Exp Clin Cancer Res. 2017 Dec 08;36(1):180
pubmed: 29216889
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Sci Rep. 2017 May 2;7(1):1312
pubmed: 28465589
J Leukoc Biol. 2000 Jan;67(1):97-103
pubmed: 10648003
J Immunol. 2000 Aug 1;165(3):1513-9
pubmed: 10903758
J Clin Invest. 1997 Jan 1;99(1):3-8
pubmed: 9011572
Sci Rep. 2019 Aug 21;9(1):12169
pubmed: 31434916
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Immunol Rev. 2008 Apr;222:155-61
pubmed: 18364000
Sarcoma. 2011;2011:842842
pubmed: 21253510
Cancers (Basel). 2019 May 24;11(5):
pubmed: 31137693
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6
pubmed: 22308361
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
PLoS One. 2015 May 04;10(5):e0126172
pubmed: 25938482
Am J Pathol. 2014 Dec;184(12):3384-93
pubmed: 25310970
Trends Immunol. 2004 Aug;25(8):450-5
pubmed: 15275645
Front Biosci. 2008 Jan 01;13:453-61
pubmed: 17981560
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Int J Cancer. 2019 Nov 15;145(10):2827-2839
pubmed: 31381136
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Mod Pathol. 2016 Sep;29(9):1028-37
pubmed: 27312065
J Immunol. 2014 Apr 15;192(8):3858-67
pubmed: 24639350
Mol Cancer Ther. 2013 Oct;12(10):1981-93
pubmed: 23939376
Front Immunol. 2019 Aug 20;10:1875
pubmed: 31481956
Br J Pharmacol. 2020 Jan 23;:
pubmed: 31975481
Oncoimmunology. 2016 Dec 7;6(2):e1265716
pubmed: 28344871
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Cancer Res. 2007 Oct 1;67(19):9518-27
pubmed: 17909062
Cancer Metastasis Rev. 2006 Sep;25(3):315-22
pubmed: 16967326
Immunity. 2018 Oct 16;49(4):595-613
pubmed: 30332628
J Cell Biol. 1989 Feb;108(2):693-702
pubmed: 2537321
Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43
pubmed: 2991901
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
J Exp Clin Cancer Res. 2019 Nov 8;38(1):459
pubmed: 31703596
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
Curr Opin Oncol. 2016 Jul;28(4):314-22
pubmed: 27166664
FEBS J. 2006 Feb;273(4):732-45
pubmed: 16441660
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Hum Pathol. 2000 Mar;31(3):341-6
pubmed: 10746677
Nature. 2016 Dec 22;540(7634):588-592
pubmed: 27974798